Home     Print Page  |  Close Window

2017 Press Releases

2017 | 2016 | 2015 | 2014
Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation for Omaveloxolone for the Treatment of Malignant Melanoma
FDA Confirms That Use of mFARS as Primary Endpoint in Part 2 of the MOXIe Trial Can Support Approval of Omaveloxolone in Friedreich’s Ataxia
Reata Pharmaceuticals, Inc. Announces Second Quarter 2017 Financial and Operating Results
Reata Announces First Patient Enrolled in Phase 3 CARDINAL Trial of Bardoxolone Methyl in the Treatment of Chronic Kidney Disease Due to Alport Syndrome
Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Reata Pharmaceuticals, Inc. Announces Pricing of Class A Common Stock Public Offering
Reata Pharmaceuticals, Inc. Announces Proposed Public Offering of Class A Common Stock
Reata’s Bardoxolone Methyl Demonstrated Improved Kidney Function in Patients With Alport Syndrome in Ongoing Phase 2 Portion of Phase 2/3 Cardinal Study
Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation for Bardoxolone Methyl for the Treatment of Alport Syndrome
Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation for Omaveloxolone for the Treatment of Friedreich’s Ataxia
Reata Pharmaceuticals, Inc. Announces Positive Data From Part One of Moxie Trial of Omaveloxolone for Friedreich’s Ataxia
Reata pharmaceuticals, inc. announces first quarter 2017 financial and operating results
Reata Pharmaceuticals, Inc. Secures $35 Million Term Loan Facility
Reata Pharmaceuticals, Inc. Appoints David Chapman as Vice President, Marketing
Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2016 Financial and Operating Results
Reata Pharmaceuticals, Inc. Announces the Retirement of Board Member Dennis Stone, M.D., and the Addition of New Board Member William D. McClellan, Jr.
Reata Announces Initiation of Phase 2/3 Study of Bardoxolone Methyl in the Treatment of Chronic Kidney Disease Due to Alport Syndrome
Reata Scheduled to Attend Upcoming Investor Conferences